BioAtla Inc
BCAB
Market Cap$23.45M
Close$
$0.63
60.2% upside
Current Fair Value
60.2% upsideUndervalued by 60.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $23.45 Million |
|---|---|
| Enterprise Value | $-8,359,975.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.44 |
| Beta | 0.91 |
| Outstanding Shares | 58,249,226 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.38 |
|---|---|
| PEG | 1.11 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.76 |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 1.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About BioAtla Inc
36 employeesBioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms...